UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Sa1373 HELICOBACTER PYLORI ERADICATION RATES WITH VONOPRAZAN: SUBGROUP ANALYSIS FROM THE PHASE 3 PHALCON HP TRIAL

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-378-S-378

2023

Volltextzugriff (PDF)

Mo1281 COMPARISON OF LOCAL INVESTIGATOR-REPORTED VS CENTRALLY ADJUDICATED LOS ANGELES GRADES OF EROSIVE ESOPHAGITIS IN PATIENTS SCREENED FOR PARTICIPATION IN A RANDOMIZED TRIAL

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1011-S-1012

2024

Volltextzugriff (PDF)

Su1205: A CLINICAL DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF VONOPRAZAN ON THE PHARMACOKINETICS OF MIDAZOLAM

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-545-S-545

2022

Volltextzugriff (PDF)

Su1202: PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUMCOMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN HEALTHY U.S. SUBJECTS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-543-S-544

2022

Volltextzugriff (PDF)

S524 Bioequivalence of Vonoprazan Sprinkle Capsule and Vonoprazan Tablet in Healthy Subjects

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S380-S381

2023

Volltextzugriff (PDF)

864 VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-198-S-198

2024

Volltextzugriff (PDF)

Su1203: NOVEL APPROACH TO EVALUATE THE IMPACT OF MODERATE AND STRONG CYP3A INDUCERS ON VONOPRAZAN EXPOSURE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-544-S-544

2022

Volltextzugriff (PDF)

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial

Clinical gastroenterology and hepatology, 2024-05

2024

Volltextzugriff (PDF)

S390 Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e272-e273

2022

Volltextzugriff (PDF)

S1387 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race and Disease Status on Exposure

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S636-S637

2021

Volltextzugriff (PDF)

S1382 Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S634-S634

2021

Volltextzugriff (PDF)

S1449 Helicobacter pylori Resistance Rates in the U.S. and Europe: Data From the PHALCON-HP Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S665-S665

2021

Volltextzugriff (PDF)

Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial

Clinical medicine insights. Urology, 2010-08, Vol.2010 (4), p.11

2010

Volltextzugriff (PDF)

Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

Drug safety, 2018-12, Vol.41 (12), p.1431-1437

2018

Volltextzugriff (PDF)

Efficacy and Safety of Oral Conivaptan: A V1A/V2 Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia

The journal of clinical endocrinology and metabolism, 2006-06, Vol.91 (6), p.2145-2152

2006

Volltextzugriff (PDF)

YM905 Safely and Effectively Treats Symptoms of Overactive Bladder

Obstetrics and gynecology (New York. 1953), 2003-04, Vol.101 (Supplement), p.116

2003

Volltextzugriff (PDF)

CONIVAPTAN, A NOVEL V1A/V2 ANTAGONIST, INCREASED SERUM SODIUM AND EFFECTIVE WATER CLEARANCE IN HYPONATREMIA CLINICAL TRIALS: 590

Critical care medicine, 2004-12, Vol.32 (Supplement), p.A166

2004

Volltextzugriff (PDF)

Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial

Clinical medicine insights. Urology, 2010-01, Vol.4, p.11

2010

Volltextzugriff (PDF)

CONIVAPTAN FOR THE TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS: RESULTS FROM AN OPEN-LABEL STUDY: 242

Critical care medicine, 2006-12, Vol.34, p.A64

2006

Volltextzugriff (PDF)

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

Current medical research and opinion, 2007-04, Vol.23 (4), p.821-831

2007

Volltextzugriff (PDF)

CONIVAPTAN, A NOVEL ARGININE VASOPRESSIN ANTAGONIST, PRODUCED AQUARESIS AND INCREASED SERUM SODIUM CONCENTRATION IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA: 234-T

Critical care medicine, 2005-12, Vol.33, p.A170

2005

Volltextzugriff (PDF)

Efficacy and safety of oral conivaptan : A V1A/V2vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

The journal of clinical endocrinology and metabolism, 2006, Vol.91 (6), p.2145-2152

2006

Volltextzugriff (PDF)

Evaluating the efficacy and safety of the novel vasopressin V1A- and V2-receptor antagonist conivaptan for the treatment of acute decompensated chronic heart failure: study protocol

Journal of cardiac failure, 2004-08, Vol.10 (4), p.S85-S85

2004

Volltextzugriff (PDF)

Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia

Journal of cardiac failure, 2004-08, Vol.10 (4), p.S27-S27

2004

Volltextzugriff (PDF)

YM905 safely and effectively treats symptoms of overactive bladder

Obstetrics and gynecology (New York. 1953), 2003-04, Vol.101 (4), p.S116-S116

2003

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Gastroenterology
(4)
Gastroesophageal Reflux
(3)
Female
(2)
Humans
(2)
Male
(2)
Overactive Bladder
(2)
Pharmacokinetics
(2)
Administration, Oral
(1)
Adolescent
(1)
Adult
(1)
African Americans
(1)
Aged
(1)
Aged, 80 And Over
(1)
Antacids
(1)
Antibiotics
(1)
Antidiuretic Hormone Receptor Antagonists
(1)
Antimicrobial Agents
(1)
Arginine Vasopressin - Blood
(1)
Art, Municipal
(1)
Asian People
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sa1373 HELICOBACTER PYLORI ERADICATION RATES WITH VONOPRAZAN: SUBGROUP ANALYSIS FROM THE PHASE 3 PHALCON HP TRIAL

Mo1281 COMPARISON OF LOCAL INVESTIGATOR-REPORTED VS CENTRALLY ADJUDICATED LOS ANGELES GRADES OF EROSIVE ESOPHAGITIS IN PATIENTS SCREENED FOR PARTICIPATION IN A RANDOMIZED TRIAL

Su1205: A CLINICAL DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF VONOPRAZAN ON THE PHARMACOKINETICS OF MIDAZOLAM

Su1202: PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUMCOMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN HEALTHY U.S. SUBJECTS

S524 Bioequivalence of Vonoprazan Sprinkle Capsule and Vonoprazan Tablet in Healthy Subjects

864 VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL

Su1203: NOVEL APPROACH TO EVALUATE THE IMPACT OF MODERATE AND STRONG CYP3A INDUCERS ON VONOPRAZAN EXPOSURE

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial

S390 Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial

S1387 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race and Disease Status on Exposure

S1382 Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication

S1449 Helicobacter pylori Resistance Rates in the U.S. and Europe: Data From the PHALCON-HP Study

Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial

Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

Efficacy and Safety of Oral Conivaptan: A V1A/V2 Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia

YM905 Safely and Effectively Treats Symptoms of Overactive Bladder

CONIVAPTAN, A NOVEL V1A/V2 ANTAGONIST, INCREASED SERUM SODIUM AND EFFECTIVE WATER CLEARANCE IN HYPONATREMIA CLINICAL TRIALS: 590

Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial

CONIVAPTAN FOR THE TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS: RESULTS FROM AN OPEN-LABEL STUDY: 242

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

CONIVAPTAN, A NOVEL ARGININE VASOPRESSIN ANTAGONIST, PRODUCED AQUARESIS AND INCREASED SERUM SODIUM CONCENTRATION IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA: 234-T

Efficacy and safety of oral conivaptan : A V1A/V2vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

Evaluating the efficacy and safety of the novel vasopressin V1A- and V2-receptor antagonist conivaptan for the treatment of acute decompensated chronic heart failure: study protocol

Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia

YM905 safely and effectively treats symptoms of overactive bladder

Aktive Filter

Suchergebnisse filtern